1 Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of teceleukin (recombinant Human Interleukin-2) after intravenous or subcutaneous administration to patients with cancer. Journal of Biological Response Modifiers, 1989, 8:440
2 List J, Moser RP, Steuer M, et al. Cytobine responses to intraventricular injection ofinterleukin-2 into patients with leptomeningeal carcinomatosis： rapid induction of tumor necrosis factors, interleukin-lp, interleukin 6, γ-interferon, and solube interlecukin 2 receptor. Cancer Research, 1992, 52:1123
3 Pais RC (Imgrim ND, Garcia ML, et al. Pharmacokinetics of recombinant IL-2 in children with mlig-nancies, J Biol Response Modifiers, 1990, 9:517
4 Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of recobinant interleukin 2 in humans. Cancer Res, 1990, 50:2009
5 Frederick J, Meyers. A phase I study including pharmacokinetics of polythylene glycol conjugated interleukin-2. Clinpharmacol ther, 1991, 49:307
6 Onishi H, Chao JTY, Lin KM, et al. Therole of the kidney in the metabolic change of IL-2. Tumour Biol 1989, 10:202
7 Onishi H, Lin KM, CHu TM, Prolongation of serum half-life of interleukin-2 and augmentation of lym-phokine-activated killer cell activity by pepstatin In mice. Cancer Res, 1990, 50:1107
8 Bocci V. Interleukins： clinical pharmacokinetics and Practical implications. Clin pharmacokinet, 1991, 21:274
9 Leahy MG, Pitfiled D, Popert Sf et al. Phase J study comparing continuous infusionof Recombinant Interleukin-2 by subcutaneous or intravenous administration. Eur J cancer, Vol. 28A, No. 6/7, 1992： 1049
10 Wittingon Rd Faulds D. Interleukin-2 A Review of it Pharmacological Properties and Therapeutics Use in Patients with cancer. Drug Ecaluation. Drugs, 1993, 46 (3)：446
11 Sculier JP, Body JJ, Donnadieu N, et al. Pharmacokinetics of repeated i. v. bolus administration of high doses of r-met-Hu interleukin-2 in advaced cancer patients. Cancer Chemither Pharmacol, 1990, 26:355 |
